Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.

ABSTRACT: To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.

SUBMITTER: Chaillon A 

PROVIDER: S-EPMC8563211 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature